Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Antifungal Noxafil Gets Priority Review For Prophylactic Use

This article was originally published in The Pink Sheet Daily

Executive Summary

A second NDA for use of posaconzole to treat oropharyngeal candidiasis was granted a standard 10-month review.

You may also be interested in...



Noxafil Gains Additional Oropharyngeal Candidiasis Indication

Approval for Schering-Plough’s antifungal comes just one month after FDA cleared it for invasive Aspergillus and Candida infections.

Noxafil Gains Additional Oropharyngeal Candidiasis Indication

Approval for Schering-Plough’s antifungal comes just one month after FDA cleared it for invasive Aspergillus and Candida infections.

Noxafil Is First FDA-Approved Antifungal For Aspergillus Infection Prevention

Schering-Plough plans to launch posaconazole for patients at high risk within two weeks.

Related Content

Topics

UsernamePublicRestriction

Register

PS063743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel